Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.